Publication List for for Bo Nordenskjöld

Publications for Bo Nordenskjöld
Co-author map based on ISI articles 2007-

Publications mentioned in social media 3 times*

Journal Articles

Josefine Bostner, Elin Karlsson, Muneeswaran J. Pandiyan, Hanna Westman, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
Breast Cancer Research and Treatment, 2013, 137(2), 397-406.

Johan Rosell, Bo Nordenskjöld, Nils-Olof Bengtsson, Tommy Fornander, Thomas Hatschek, Henrik Lindman, Per-Olof Malmstrom, Arne Wallgren, Olle Stål and John Carstensen
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up

Altmetric usage: 2

Breast Cancer Research and Treatment, 2013, 138(2), 467-473.

Helena Fohlin, Gizeh Perez-Tenorio, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld, John Carstensen and Olle Stål
Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

Altmetric usage: 1

European Journal of Cancer, 2013, 49(6), 1196-1204.

Tove Sivik, Cecilia Gunnarsson, Tommy Fornander, Bo Nordenskjöld, Lambert Skoog, Olle Stål and Agneta Jansson
17β-hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer
PLoS ONE, 2012, 7(7), e40568.

Web of Science® Times Cited: 1

Gizeh Perez-Tenorio, Elin Karlsson, Marie Ahnström, Birgit Olsson, Birgitta Holmlund, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
Breast Cancer Research and Treatment, 2011, 128(3), 713-723.

Fulltext

Web of Science® Times Cited: 4

Piiha-Lotta Jerevall, Xiai-Jun Ma, Hongying Li, Ranelle Salunga, Nicole C. Kesty, Mark G. Erlander, Dennis Sgroi, Birgitta Holmlund, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
Prognostic utility of HOXB13:IL17BR and Molecular Grade Index in early-stage breast cancer patients from the Stockholm trial
British Journal of Cancer, 2011, 104(11), 1762-1769.

Fulltext

Web of Science® Times Cited: 10

Johan Rosell, Bo Nordenskjöld, N-O Bengtsson, T Fornander, T Hatschek, H Lindman, P-O Malmstrom, A Wallgren, Olle Stål and John Carstensen
Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
BRITISH JOURNAL OF CANCER, 2011, 104(6), 899-902.

Web of Science® Times Cited: 2

Mahmoud R Khoshnoud, Britta Lofdahl, Helena Fohlin, Tommy Fornander, Olle Stål, Lambert Skoog, Jonas Bergh and Bo Nordenskjöld
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
Breast Cancer Research and Treatment, 2011, 126(2), 421-430.

Web of Science® Times Cited: 9

Piiha-Lotta Jerevall, Agneta Jansson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
Breast Cancer Research, 2010, 12(4), .

Web of Science® Times Cited: 6

Josefine Bostner, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld and Olle Stål
Estrogen Receptor-alpha Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Clinical Cancer Research, 2010, 16(5), 1624-1633.

Fulltext

Web of Science® Times Cited: 10

B. C. Sanchez, M. Sundqvist, Helena Fohlin, F. Spyratos, Bo Nordenskjöld, Olle Stål, B. K and Linderholm
Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF
European Journal of Cancer, 2010, 46(9), 1580-1587.

Web of Science® Times Cited: 2

Ann-Christine Kallstrom, Rebecka Salme, Lisa Ryden, Bo Nordenskjöld, Per-Ebbe Jonsson and Olle Stål
17 beta-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
EUROPEAN JOURNAL OF CANCER, 2010, 46(5), 892-900.

Web of Science® Times Cited: 5

Evandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, Emmanuel Quinaux, John P A Crown, Malou Vicente, Rosa Giuliani, Bo Nordenskjöld, Jorge Gutierez, Michael Andersson, Mireia Margeli Vila, Raimund Jakesz, Jan Demol, Joanna Dewar, Armando Santoro, Ana Lluch, Steven Olsen, Richard D Gelber, Angelo Di Leo and Martine Piccart-Gebhart
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
Breast Cancer Research and Treatment, 2010, 119(1), 145-153.

Web of Science® Times Cited: 25

K Lundgren, Bo Nordenskjöld and G Landberg
Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer
BRITISH JOURNAL OF CANCER, 2009, 101(10), 1769-1781.

Web of Science® Times Cited: 23

S. Alkner, P.-O. Bendahl, M. Ferno, Bo Nordenskjöld and L. Ryden
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial
European Journal of Cancer, 2009, 45(14), 2496-2502.

Web of Science® Times Cited: 9

Agneta Jansson, Lovisa Delander, Cecilia Gunnarsson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Clinical Cancer Research, 2009, 15(10), 3610-3616.

Web of Science® Times Cited: 9

Patrik Johansson, Helena Fohlin, Lars-Gunnar Arnesson, Monika Dufmats, Kerstin Nordenskjoeld, Bo Nordenskjöld and Olle Stål
Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy
ACTA ONCOLOGICA, 2009, 48(4), 504-513.

Fulltext

Web of Science® Times Cited: 2

Allan Hackshaw, Michael Baum, Tommy Fornander, Bo Nordenskjöld, Antonio Nicolucci, Kathryn Monson, Sharon Forsyth, Krystyna Reczko, Ulla Johansson, Helena Fohlin, Miriam Valentini and Richard Sainsbury
Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101(5), 341-349.

Web of Science® Times Cited: 14

Marie Ahnström, Marie Askmalm Stenmark, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer
International Journal of Oncology, 2009, 34(2), 441-448.

Web of Science® Times Cited: 5

Gizeh Perez-Tenorio, Elin Karlsson, Marie Ahnström Waltersson, Birgit Olsson, Birgitta Holmlund, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog and Olle Stål
Clinical Value of RPS6KB1 and RPS6KB2 Gene Amplification in Postmenopausal Breast Cancer
, 2008, , .

Emma Niméus-Malmström, Morten Krogh, Per Malmström, Carina Strand, Irma Fredriksson, Per Karlsson, Bo Nordenskjöld, Olle Stål, Görel Östberg, Carsten Peterson and Marten Ferno
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy
Breast Cancer Research, 2008, 10(2), .

Web of Science® Times Cited: 17

P Berglund, M Stighall, K Jirström, L Rydén, M Ferno, Bo Nordenskjöld and G Landberg
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern
Journal of Clinical Pathology, 2008, 61(2), 184-191.

Web of Science® Times Cited: 5

Prudence Francis, John Crown, Angelo Di Leo, Marc Buyse, Ana Balil, Michael Andersson, Bo Nordenskjöld, Istvan Lang, Raimund Jakesz, Daniel Vorobiof, Jorge Gutiérrez, Guy van Hazel, Stella Dolci, Sophie Jamin, Belguendouz Bendahmane, Richard D. Gelber, Aron Goldhirsch, Monica Castiglione-Gertsch and Martine Piccart-Gebhart
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial
Journal of the National Cancer Institute, 2008, 100(2), 121-133.

Web of Science® Times Cited: 72

Bent Kristensen, Bent Ejlertsen, Henning T. Mouridsen, Maj-Britt Jensen, Jørn Andersen, Brita Bjerregaard, Søren Cold, Per Edlund, Marianne Ewertz, Claus Kamby, Henrik Lindman, Bo Nordenskjöld and Jonas Bergh
Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
Acta Oncologica, 2008, 47(4), 740-746.

Web of Science® Times Cited: 33

B. C. Pestalozzi, P. Francis, E. Quinaux, S. Dolci, E. Azambuja, R. D. Gelber, G. Viale, A. Balil, M. Andersson, Bo Nordenskjöld, M. Gnant, J. Gutierrez, I. Láng, J. P. A. Crown and M. Piccart-Gebhart
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial
Annals of Oncology, 2008, 19(11), 1837-1841.

Lisa Rydén, Göran Landberg, Olle Stål, Bo Nordenskjöld, Mårten Fernö and Pär-Ola Bendahl
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
Breast Cancer Research and Treatment, 2008, 109(2), 351-357.

Web of Science® Times Cited: 19

Barbara E. Licznerska, Pia P. Wegman, Bo Nordenskjöld and Sten Wingren
In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients
Breast Cancer Research and Treatment, 2008, 112(1), 15-23.

Cecilia Gunnarsson, Piiha-Lotta Jerevall, Karl Hammar, Birgit Olsson, Bo Nordenskjöld, Agneta Jansson and Olle Stål
Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer
Breast Cancer Research and Treatment, 2008, 108(1), 35-41.

Web of Science® Times Cited: 16

Piiha-Lotta Jerevall, Sara Brommesson, Carina Strand, Sofia Gruvberger-Saal, Per Malmström, Bo Nordenskjöld, Sten Wingren, Peter Söderkvist, Mårten Fernö and Olle Stål
Exploring the two-gene ratio in breast cancer – independent roles for HOXB13 and IL17BR in prediction of clinical outcome
Breast Cancer Research and Treatment, 2008, 107(2), 225-234.

Fulltext

Web of Science® Times Cited: 23

Katja Lundgren, Karolina Holm, Bo Nordenskjöld, Ake Borg and Goran Landberg
Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
Breast cancer research, 2008, 10(5), R81.

Fulltext

Karin Söderlund Leifler, Olle ¨, Lambert Skoog, Lars Erik Rutqvist, Bo Nordenskjöld and Marie Stenmark Askmalm
Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer
International Journal of Radiation Oncology, Biology, Physics, 2007, 68(1), 50-58.

Web of Science® Times Cited: 22

Gizeh Pérez-Tenorio, Liza Alkhori, Birgit Olsson, Marie Ahnstro Waltersson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer
Clinical Cancer Research, 2007, 13(12), 3577-3584.

B. Ejlertsen, H.T. Mouridsen, M.-B. Jensen, J. Andersen, S. Cold, P. Edlund, M. Ewertz, B.B. Jensen, C. Kamby, Bo Nordenskjöld and J. Bergh
Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
European Journal of Cancer, 2007, 43(5), 877-884.

Web of Science® Times Cited: 31

Pia Wegman Palmebäck, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld and Sten Wingren
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients
Breast Cancer Research, 2007, 9(1), R7.

Fulltext

Web of Science® Times Cited: 131

Josefine Bostner, Marie Ahnström Waltersson, T Fornander, L Skoog, Bo Nordenskjöld and Olle Stål
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Oncogene, 2007, 26(49), 6997-7005.

Web of Science® Times Cited: 43

Pia Wegman (Palmebäck), Olle Stål, Marie Stenmark Askmalm, Bo Nordenskjöld, Lars-Erik Rutqvist and Sten Wingren
p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
Pharmacogenetics and Genomics, 2006, 16(5), 347-351.

Web of Science® Times Cited: 13

Gizeh Perez-Tenorio, Fredrik Berglund, Anna Esguerra Merca, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
Cytoplasmic p21^WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer
International Journal of Oncology, 2006, 28(5), 1031-1042.

Web of Science® Times Cited: 19

M. Stendahl, L. Ryden, Bo Nordenskjöld, P.E. Jonsson, G. Landberg and K. Jirstrom
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients
Clinical Cancer Research, 2006, 12(15), 4614-4618.

Web of Science® Times Cited: 49

A Kronblad, K Jirström, L Rydén, Bo Nordenskjöld and G Landberg
Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response
International Journal of Cancer, 2006, 118(10), 2609-2616.

Web of Science® Times Cited: 36

Cecilia Gunnarsson, Agneta Jansson, Birgitta Holmlund, Lilianne Ferraud, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
Expression of COX-2 and steroid converting enzymes in breast cancer
Oncology Reports, 2006, 16(2), 219-224.

Web of Science® Times Cited: 6

L Ryden, K Jirstrom, PA Bendahl, M Ferno, Bo Nordenskjöld, Olle Stål, Sten Thorstenson, PE Jonsson and G Landberg
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer
Journal of Clinical Oncology, 2005, 23(21), 4695-4704.

Web of Science® Times Cited: 51

Bo Nordenskjöld, Johan Rosell, Lars-Erik Rutqvist, Per-Olof Malmström, Jonas Bergh, Nils-Olof Bengtsson, Thomas Hatschek, Arne Wallgren and John Carstensen
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
Journal of the National Cancer Institute, 2005, 97(21), 1609-1610.

Web of Science® Times Cited: 34

K Jirström, L Rydén, L Anagnostaki, Bo Nordenskjöld, Olle Stål, S Thorstenson, G Chebil, P-E Jönsson, M Fernö and G Landberg
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
Journal of Clinical Pathology, 2005, 58(11), 1135-1142.

Web of Science® Times Cited: 22

Lisa Rydén, Per-Ebbe Jönsson, Gunilla Chebil, Monika Dufmats, Mårten Fernö, Karin Jirström, Ann-Christine Källström, Göran Landberg, Olle Stål, Sten Thorstenson and Bo Nordenskjöld
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
European Journal of Cancer, 2005, 41(2), 256-264.

Web of Science® Times Cited: 47

Pia Wegman (Palmebäck), Linda Vainikka, Olle Stål, Bo Nordenskjöld, Lambert Skoog, Lars-Erik Rutqvist and Sten Wingren
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
Breast Cancer Research, 2005, 7(3), R284-R290.

Fulltext

Web of Science® Times Cited: 110

Marie Ahnström Waltersson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance.
Breast Cancer Research and Treatment, 2005, 91(2), 145-151.

Web of Science® Times Cited: 20

Marie Stenmark Askmalm, John Carstensen, Bo Nordenskjöld, Birgit Olsson, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients
Acta Oncologica, 2004, 43(3), 235-244.

Web of Science® Times Cited: 11

G Tejler, B Norberg, Monika Dufmats, Bo Nordenskjöld and Lars-Gunnar Arnesson
Survival after treatment for breast cancer in a geographically defined population
British Journal of Surgery, 2004, 91(10), 1307-1312.

Web of Science® Times Cited: 11

Olle Stål, Gizeh Perez-Tenorio, Lind Åkerberg, Birgit Olsson, Bo Nordenskjöld, Lambert Skoog and Lars Rutqvist
Akt kinases in breast cancer and the results of adjuvant therapy
Breast Cancer Research, 2003, 5(2), R37-R44.

Web of Science® Times Cited: 89

Cecilia Gunnarsson, Marie Ahnström, Kristina Kirschner, Birgit Olsson, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
Amplification of HSD17B1 and ERBB2 in primary breast cancer
Oncogene, 2003, 22(1), 34-40.

Web of Science® Times Cited: 50

Marie Sundquist, Sten Thorstenson, Lars Brudin, Sten Wingren and Bo Nordenskjöld
Incidence and prognosis in early onset breast cancer
Breast, 2002, 11(1), 30-35.

Web of Science® Times Cited: 17

Lasse Karlsson, Anders Håkansson and Bo Nordenskjöld
Opportunistisk cancerscreening i primärvård
Läkartidningen, 2002, 99, 2636-2638.

Sören Mattsson, Anders Brahme, Jörgen Carlsson, Juliana Denekamp, Eva Forssell-Aronsson, Mikael Hellström, Karl-Axel Johansson, Elisabeth Kjellén, Bo Littbrand, Bo Nordenskjöld, Bo Stenerlöw, Ingela Turesson, Björn Zackrisson and Bengt Glimelius
Swedish Cancer Society radiation therapy research investigation
Acta Oncologica, 2002, 41(7-8), 596-603.

Web of Science® Times Cited: 13

Bengt Glimelius, Bo Nordenskjöld, Elisabeth Kjellén and Björn Zackrisson
Interactions between chemotherapy, endocrine therapy and radiation
Acta Oncologica, 2002, 41(7-8), 635-638.

Web of Science® Times Cited: 5

Lennarth Nyström, Ingvar Andersson, Nils Bjurstam, Jan Frisell, Bo Nordenskjöld and Lars Erik Rutqvist
Long-term effects of mammography screening: Updated overview of the Swedish randomised trials
The Lancet, 2002, 359(9310), 909-919.

Web of Science® Times Cited: 491

L Carlsson, Annika Håkansson and Bo Nordenskjöld
Common cancer-related symptoms among GP patients - Opportunistic screening in primary health care
Scandinavian Journal of Primary Health Care, 2001, 19(3), 199-203.

Web of Science® Times Cited: 7

Gunnar Adell, Hong Zhang, Agneta Jansson, Xiao-Feng Sun, Olle Stål and Bo Nordenskjöld
Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer
International Journal of Radiation Oncology, Biology, Physics, 2001, 50(3), 659-663.

Web of Science® Times Cited: 28

Gunnar C. E. Adell, Hong Zhang, Sofia Evertsson, Xiao-Feng Sun, Olle Stål and Bo Nordenskjöld
Apoptosis in rectal carcinoma: Prognosis and recurrence after preoperative radiotherapy
Cancer, 2001, 91(10), 1870-1875.

Web of Science® Times Cited: 29

Marie Sundquist, Sten Thorstenson, Lars Brudin, Olle Stål and Bo Nordenskjöld
A comparison between flow cytometric assessment of S-phase fraction and Nottingham histologic grade as prognostic instruments in breast cancer
Breast Cancer Research and Treatment, 2000, 63(1), 11-15.